GlaxoSmithKline plc (GSK) Rating Reiterated by Liberum Capital
Liberum Capital reiterated their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note released on Thursday morning. Liberum Capital currently has a GBX 1,900 ($24.75) target price on the stock.
Other research analysts also recently issued reports about the company. UBS AG set a GBX 1,600 ($20.84) price target on GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Thursday, April 27th. Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a GBX 1,900 ($24.75) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Bryan, Garnier & Co reissued a buy rating and issued a GBX 1,750 ($22.80) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Deutsche Bank AG reissued a hold rating and issued a GBX 1,720 ($22.41) price objective on shares of GlaxoSmithKline plc in a research note on Friday, June 30th. Finally, Jefferies Group LLC lowered their price objective on GlaxoSmithKline plc from GBX 1,850 ($24.10) to GBX 1,800 ($23.45) and set a buy rating for the company in a research note on Thursday, April 20th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. The company has an average rating of Hold and an average price target of GBX 1,734.73 ($22.60).
GlaxoSmithKline plc (GSK) opened at 1526.00 on Thursday. The company’s market capitalization is GBX 74.59 billion. The firm has a 50-day moving average price of GBX 1,638.77 and a 200-day moving average price of GBX 1,627.17. GlaxoSmithKline plc has a 1-year low of GBX 1,446.50 and a 1-year high of GBX 1,745.56.
The company also recently disclosed a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be issued a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
In related news, insider Patrick Vallance bought 861 shares of the company’s stock in a transaction on Friday, July 14th. The shares were purchased at an average price of GBX 1,618 ($21.08) per share, for a total transaction of £13,930.98 ($18,148.75). Also, insider Manvinder Singh Banga bought 2,267 shares of the company’s stock in a transaction on Wednesday, July 26th. The shares were bought at an average price of GBX 1,599 ($20.83) per share, for a total transaction of £36,249.33 ($47,224.24). Over the last three months, insiders have acquired 3,150 shares of company stock valued at $5,054,075.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.